https://burns-media.com/biotech/ The catalyst calendar for biotech investors. Published weekday mornings by Burns Media. en-us © 2026 Burns Media 60 Sat, 18 Apr 2026 21:09:44 +0000 https://burns-media.com/assets/social/biotech_fda.png https://burns-media.com/biotech/ https://burns-media.com/biotech/archive/2026-04-18 https://burns-media.com/biotech/archive/2026-04-18 Sat, 18 Apr 2026 07:00:00 +0000 UCB's acquisition diversifies its epilepsy treatment portfolio amid rising competition. UCB is set to acquire Neurona for up to $1.2B, aiming to enhance its portfolio in seizure therapies. This move comes as competition intensifies in the epilepsy treatment market.

Top stories

• UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
  UCB's acquisition of Neurona will bolster its offerings in treating epilepsy, specifically targeting hard-to-treat forms. The deal includes an upfront payment along with milestone payments based on Neurona's future performance.
• Trump issues executive order on psychedelic drugs
  Former President Trump signed an executive order aimed at easing restrictions on psychedelic research and therapies, potentially opening new avenues for companies in this emerging sector. This could lead to increased funding and regulatory support for clinical trials.
• RevMed’s stunning success; FDA to reclassify peptides; and more
  Revolution Medicines reported groundbreaking results from its pan-RAS drug, significantly improving survival in pancreatic cancer patients. The FDA is also considering reclassifying peptides, which could impact various biotech companies involved in peptide therapies.
• Targeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Models
  A new lung-targeted gene delivery method has shown promise in reducing inflammation and tissue damage in infected mice, potentially leading to more precise treatments for severe respiratory infections. This innovation could pave the way for new therapies that avoid systemic immune effects.
• Novo obesity drug outperforms Lilly’s in preserving lean body mass: study
  Novo Nordisk's new obesity treatment demonstrated superior efficacy in preserving lean body mass compared to Eli Lilly's competing product, which could shift market dynamics in the obesity drug sector. This finding may influence prescribing patterns and patient outcomes.

Quick hits

• Alamar's stock surged 40% following an upsized IPO, raising significant capital for growth.
• Kailera Therapeutics raised $625 million in its IPO, focusing on obesity treatments.
• FDA is reviewing new data on testosterone therapy, potentially expanding its indications for libido enhancement.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-17 https://burns-media.com/biotech/archive/2026-04-17 Fri, 17 Apr 2026 07:00:00 +0000 UCB's acquisition of Neurona marks a strategic move into cell therapy for epilepsy. In today's briefing, UCB's significant acquisition of Neurona highlights a strategic expansion in their epilepsy treatment portfolio. This move could reshape the landscape for seizure therapies.

Top stories

• UCB to Acquire Neurona for Up to $1.2B, Expanding Epilepsy Treatments
  UCB has announced plans to acquire Neurona for up to $1.2 billion, aiming to diversify its offerings in seizure treatments with a promising cell therapy currently in early testing. This acquisition aligns with UCB's strategy to enhance its pipeline for hard-to-treat forms of epilepsy. Investors will be watching closely to see how this integration impacts UCB's growth and innovation in the neurology space.
• Revolution Medicines' Pancreatic Cancer Breakthrough Boosts Valuation
  Revolution Medicines has reported successful Phase 3 results for its targeted 'pan-RAS' drug, which significantly improved survival rates in patients with recurrent pancreatic cancer. This data has reportedly increased the company's buyout price, reflecting heightened interest from potential acquirers. The results position Revolution as a key player in the oncology space, particularly for hard-to-treat cancers.
• Targeted Gene Delivery Shows Promise in Lung Inflammation Treatment
  Recent studies demonstrated that a lung-targeted gene delivery system effectively reduced harmful inflammation in mouse models of respiratory infection, without triggering systemic immune responses. This approach could pave the way for more precise therapies for severe infections, addressing a significant clinical need. Researchers are optimistic about the potential applications in human medicine, particularly for respiratory diseases.
• Kailera Therapeutics Raises $625M in Record-Setting IPO
  Kailera Therapeutics successfully raised $625 million through its IPO on Nasdaq, pricing shares at $16 each. Backed by Bain Capital Life Sciences, Kailera aims to advance its pipeline focusing on obesity treatments. This significant capital influx positions Kailera to accelerate its development efforts in a competitive market.
• FDA Prepares for GDUFA IV Reauthorization, Implications for Generic Drugs
  The FDA is gearing up for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA), with information being made available for industry stakeholders. This reauthorization process is crucial for ensuring the continued efficiency and effectiveness of the generic drug approval process. Stakeholders will be keen to understand the implications of any changes that may arise from this reauthorization.

Quick hits

• Alamar Therapeutics sees a 40% increase following its upsized IPO.
• Novo Nordisk's obesity drug outperforms Lilly's in preserving lean body mass.
• FDA eyes expanding testosterone therapy for libido based on new research.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-12 https://burns-media.com/biotech/archive/2026-04-12 Sun, 12 Apr 2026 07:00:00 +0000 Replimune faces regulatory challenges as FDA denies melanoma treatment again. In a significant setback for Replimune, the FDA has rejected its melanoma candidate RP1 for the second time. This decision underscores ongoing regulatory scrutiny in drug approvals.

Top stories

• FDA Rejects Replimune's Melanoma Prospect for Second Time
  The FDA has once again denied Replimune's application for its melanoma drug RP1 due to unresolved issues with the study results. This marks a critical moment for the company as it struggles to meet regulatory expectations, which could impact its future funding and strategic direction. Investors should watch for potential implications on Replimune's stock as the company navigates these challenges.

Quick hits

• Oricell raises over $110M for CAR-T therapy targeting solid tumors ahead of an IPO.
• Lilly launches Foundayo, a GLP-1 oral medication, entering a competitive obesity market.
• Avalyn plans an IPO to fund phase 3 trials for inhaled versions of respiratory drugs.

Read the full briefing →

]]> Biotech